Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials.
about
Natural products as aromatase inhibitorsPotential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics.Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator.Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomicsAromatase inhibitors in post-menopausal metastatic breast carcinoma.Treatment of breast cancer in older women.Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cellsRole of the UGT2B17 deletion in exemestane pharmacogenetics.Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast CancerEmerging drugs in metastatic breast cancer
P2860
Q24620153-35FFC60F-9A7C-41A5-9ADA-AC5B7128BE68Q34774040-51D40839-A3D0-4F78-9739-493E004260D1Q34793489-D57BA3B7-C4F3-477D-A74D-8641330C9AABQ36095148-97666C19-3933-4D24-96FD-42875A72F8FDQ36717159-64C0585E-B394-462D-BBA4-FFEC110CA871Q36861597-FDF074DC-8CE6-4AB8-93A9-66FD6B494271Q36953425-6428C586-8B4F-4CEE-9F1E-699F137E6A81Q37401741-B0A395B5-BD8A-4E19-9951-1C2FF10606F0Q38769425-117D0551-93F4-4FB9-87BE-4C10221A3A60Q39185424-082673C6-7A08-48CA-857A-01A8B926C984Q41521650-52D1889A-6B48-4FD5-BD5B-F17E99F0290BQ57108041-C0775E18-FB55-4A05-A9EC-BCB7692A1FCCQ57142532-AEC88A0B-A9FB-4FF6-9E4D-08041BEC675F
P2860
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Second- and third-generation a ...... ysis of the randomised trials.
@ast
Second- and third-generation a ...... ysis of the randomised trials.
@en
type
label
Second- and third-generation a ...... ysis of the randomised trials.
@ast
Second- and third-generation a ...... ysis of the randomised trials.
@en
prefLabel
Second- and third-generation a ...... ysis of the randomised trials.
@ast
Second- and third-generation a ...... ysis of the randomised trials.
@en
P2093
P2860
P50
P356
P1476
Second- and third-generation a ...... lysis of the randomised trials
@en
P2093
A Gelibter
E M Ruggeri
F Cognetti
F L Cecere
G Ferretti
M Ciccarese
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603194
P407
P577
2006-05-30T00:00:00Z